Heterogeneity in CBF beta/MYH11 fusion messages encoded by the inv(16)(p13q22) and the t(16;16)(p13;q22) in acute myelogenous leukemia
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Inv(16)(p13q22) is one of the most frequent chromosomal rearrangements found in acute myelogenous leukemia (AML), representing approximately 16% of documented karyotypic abnormalities. The inv(16) breakpoints have been cloned and shown to involve the non-DNA binding component of the AML-1 transcription factor complex termed core binding factor beta gene (CBF beta) on 16q and the smooth muscle myosin heavy chain gene (MYH11) on 16p. In this study, we analyzed 37 cases of inv(16)-containing AML and 4 cases with t(16;16)(p13;q22) for expression of the CBF beta/MYH11 chimeric message by reverse transcription-polymerase chain reaction (PCR) analysis. CBF beta/MYH11 chimeric messages were detected in 33 of 37 cases with the inv(16) and in the 4 t(16;16)-containing cases. Sequence analysis of PCR products showed extensive breakpoint heterogeneity in both CBF beta and MYH11. In addition to the previously described breakpoint in CBF beta at nucleotide (nt) 495 (amino acid 165), we have identified a second novel fusion point at nt 399 (amino acid 133) in 7% of the cases. Similarly, a unique breakpoint site was identified in MYH11 at nt 1098, as well as at three previously characterized sites at nts 994, 1201, and 1921. Of the 4 PCR-negative cases, 2 of 3 tested lacked CBF beta rearrangements by Southern blot analysis, suggesting the possible involvement of a different genomic locus in some cases with cytogenetic evidence of inv(16). To assess whether the portions of CBF-beta contained within the CBF beta/MYH11 chimeric products retain the ability to interact with their heterodimeric DNA-binding partner AML-1, we performed in vitro DNA- binding analysis. Recombinant CBF-beta polypeptides consisting of the N-terminal 165 amino acids retained their ability to interact with AML-1, whereas mutants containing only the N-terminal 133 amino acids interacted with AML-1 less efficiently. These data suggest that different CBF beta/MYH11 products may vary subtly in their biologic activities.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A fourth alteration, inv (16), is observed in AML of the M4Eo subtype (French-American-British classification) and indirectly targets AML-1B by fusing CBF-, the gene for the heterodimeric DNA binding partner of AML-1B (71), to the smooth muscle myosin heavy chain gene, MYH11 (35,64).”
From The t(8;21) Fusion Product, AML-1–ETO, Associates with C/EBP-α, Inhibits C/EBP-α-Dependent Transcription, and Blocks Granulocytic Differentiation (1998) · cites this paper as [64]
Citations
Cites
Detection of specific sequences among DNA fragments separated by gel electrophoresis
Southern, E. M. (1975) · Journal of Molecular Biology · doi:10.1016/s0022-2836(75)80083-0 · Cited by 32,249
Avoiding false positives with PCR
Kwok, S., & Higuchi, R. (1989) · Nature · doi:10.1038/339237a0 · Cited by 3,441
Miyoshi, H., Shimizu, K., Kozu, T., Maseki, N., Kaneko, Y., & Ohki, M. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.23.10431 · Cited by 872
Fusion Between Transcription Factor CBFβ/PEBP2β and a Myosin Heavy Chain in Acute Myeloid Leukemia
Liu, P., Tarlé, S. A., Hajra, A., Claxton, D. F., Marlton, P., Freedman, M., Siciliano, M. J., & Collins, F. S. (1993) · Science · doi:10.1126/science.8351518 · Cited by 732
Erickson, P., Gao, J., Chang, K., Look, T., Whisenant, E., Raimondi, S., Lasher, R., Trujillo, J., Rowley, J., & Drabkin, H. (1992) · Blood · doi:10.1182/blood.v80.7.1825.1825 · Cited by 631
Self-citationOgawa, E., Maruyama, M., Kagoshima, H., Inuzuka, M., Lu, J., Satake, M., Shigesada, K., & Ito, Y. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.14.6859 · Cited by 608
Ogawa, E., Inuzuka, M., Maruyama, M., Satake, M., Naito-Fujimoto, M., Ito, Y., & Shigesada, K. (1993) · Virology · doi:10.1006/viro.1993.1262 · Cited by 493
Le Beau, M. M., Larson, R. A., Bitter, M. A., Vardiman, J. W., Golomb, H. M., & Rowley, J. D. (1983) · New England Journal of Medicine · doi:10.1056/nejm198309153091103 · Cited by 492
Wang, S., Wang, Q., Crute, B. E., Melnikova, I. N., Keller, S. R., & Speck, N. A. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.6.3324-3339.1993 · Cited by 435
The t(8;21) Fusion Protein Interferes with AML-1B-Dependent Transcriptional Activation
Meyers, S., Lenny, N., & Hiebert, S. W. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.4.1974 · Cited by 368
Self-citation
Cited by
The World Health Organization (WHO) classification of the myeloid neoplasms
Vardiman, J. W., Harris, N. L., & Brunning, R. D. (2002) · Blood · doi:10.1182/blood-2002-04-1199 · Cited by 2,197
Okuda, T., van Deursen, J., Hiebert, S. W., Grosveld, G., & Downing, J. R. (1996) · Cell · doi:10.1016/s0092-8674(00)80986-1 · Cited by 1,856
“…directly binds the enhancer core phenotype, despite the complete lack of cytogenetic DNA sequence TGT/cGGT, which is present in a number evidence of this translocation in the majority of cases of different viral and cellular promoters and enhancers (Romana et al., 1995b; Shurtleff et al., 1995b).”
Self-citationLowenberg, B., Downing, J. R., & Burnett, A. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909303411407 · Cited by 1,217
van Dongen, J., Macintyre, E., Gabert, J., Delabesse, E., Rossi, V, Saglio, G., Gottardi, E., Rambaldi, A., Dotti, G., Griesinger, F., et al. (1999) · Leukemia · doi:10.1038/sj.leu.2401592 · Cited by 1,169
The CBFβ Subunit Is Essential for CBFα2 (AML1) Function In Vivo
Wang, Q., Stacy, T., Miller, J. D., Lewis, A. F., Gu, T.-L., Huang, X., Bushweller, J. H., Bories, J.-C., Alt, F. W., Ryan, G., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81389-6 · Cited by 621
Metadata
- Authors
- Shurtleff, S., Meyers, S., Hiebert, S., Raimondi, S., Head, D., Willman, C., Wolman, S., Slovak, M., Carroll, A., & Behm, F.
- Affiliations
- St. Jude Children's Research Hospital (US)
- Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 1995-06-15
- Volume
- 85
- Issue
- 12
- Pages
- 3695-3703
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1533510727
- Cited by
- 102
- References
- 23
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2022: 1 · 2021: 2 · 2019: 2 · 2017: 1 · 2015: 2 · 2014: 1 · 2013: 3 · 2012: 5
- FWCI
- 4.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5k08ca001429-05)
- National Cancer Institute (CA64140, CA-32102, U10CA032102, R01CA064140, CA 01429)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomic variations and chromosomal abnormalities
- Keywords
- CBFβ, MYH11, inv(16)(p13q22), acute myeloid leukemia, fusion transcripts, core binding factor beta, myosin heavy chain, DNA-binding activity, AML1-ETO fusion
- MeSH terms
- Adolescent, Adult, Aged, Amino Acid Sequence, Base Sequence, Child, Child, Preschool, Chromosome Aberrations, Chromosomes, Human, Pair 22, Cloning, Molecular, DNA-Binding Proteins, Female, Humans, Male, Middle Aged, Molecular Sequence Data, Myosins, Neoplasm Proteins, Recombinant Fusion Proteins, Transcription Factors, Leukemia, Myeloid, Acute, Core Binding Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Heterogeneity in CBF beta/MYH11 fusion messages encoded by the inv(16)(p13q22) and the t(16;16)(p13;q22) in acute myelogenous leukemia. https://app.cochat.ai/papers/10.1182/blood.v85.12.3695.bloodjournal85123695
- The paper
- Shurtleff, S., Meyers, S., Hiebert, S., Raimondi, S., Head, D., Willman, C., Wolman, S., Slovak, M., Carroll, A., & Behm, F. (1995). Heterogeneity in CBF beta/MYH11 fusion messages encoded by the inv(16)(p13q22) and the t(16;16)(p13;q22) in acute myelogenous leukemia. Blood. https://doi.org/10.1182/blood.v85.12.3695.bloodjournal85123695
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.